ArticleTranslational lung cancer research2026
Surgical strategy after neoadjuvant immunochemotherapy for central-type NSCLC: restaging-guided versus pre-treatment-guided decision-making.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective neoadjuvant immunochemotherapy (nICT) can downstage central-type non-small cell lung cancer (NSCLC) and reopen previously obstructed bronchi, but surgical decisions are frequently still anchored to pre-treatment staging. This study aimed to evaluate whether a standardized post-nICT restaging-guided surgical strategy could safely support surgical de-escalation while maintaining oncologic safety in selected patients with central-type NSCLC. Methods: We conducted a single-center retrospective cohort study of central-type NSCLC involving or abutting the lobar/main bronchus, initially considered to require at least sleeve resection or pneumonectomy. Patients with clinical stage I-III disease who received platinum-based nICT and subsequently showed radiologic partial response (PR)/complete response (CR) and no visible residual endobronchial tumor were included. Surgical management followed either a pre-nICT staging-guided surgery (TN-pre) or a post-nICT restaging-guided surgery (PRS), which linked specific post-nICT computed tomography (CT) and bronchoscopic criteria to de-escalation from pneumonectomy/sleeve resection to lobectomy when R0 resection was deemed feasible. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances. We compared pathologic response, margin status, perioperative outcomes, overall survival (OS), disease-free survival (DFS), and recurrence patterns. Results: A total of 122 patients were analyzed (78 PRS, 44 TN-pre). After IPTW, demographic and clinicopathologic features were well balanced. Post-neoadjuvant therapy pathologic tumor-node-metastasis (ypTNM) stage distribution, major pathological response (MPR) rates (83.6% Conclusions: A post-treatment restaging-guided strategy that explicitly incorporates CT and bronchoscopic response allows safe de-escalation of surgery in selected central-type NSCLC after nICT, converting many planned pneumonectomies or sleeve resections to lobectomy. This response-adapted approach improves perioperative metrics without an early detrimental impact on oncologic outcomes. However, these survival findings should be considered hypothesis-generating and warrant further validation through long-term prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.